The tasks of the CEO and other senior executives

The CEO is appointed by the board of directors and handles the Group’s daily management according to the board’s guidelines and instructions.

The CEO is responsible for keeping the board informed about the Group’s development and for reporting significant deviations from established business plans and events that have great impact on the Group’s development and operations, and for preparing relevant reports and information for the board’s decisions on e.g. establishments, investments and other strategic issues. The Group’s management team is led by the Company’s CEO Gunilla Osswald and consists of persons with responsibility for significant areas of operations at BioArctic.

Gunilla Osswald is the Company’s CEO. Other senior executives in the Company are Chief Financial Officer Jan Mattsson, Communications Director Christina Astrén Eriksson, Chief Scientific Officer Christer Möller, Chief Medical Officer Hans Basun, Head of the Department for Immunology and Pharmacology Johanna Fälting, Head of the Department for Biochemistry and Molecular Biology Mikael Moge and responsible for Quality Assurance Mats Holmquist.

In addition to the above persons board member Pär Gellerfors is also a co-opted member of the management team.

Name Position Member of Senior
management since
Employed in the
Company since
Holdings in BioArctic (1)
SH CO
Gunilla Osswald CEO

2013

2013  12,800 B-shares

5 818 (2)

Jan Mattsson CFO

2017

2017 15,000 B-shares

 1,818 (3)

Christina Astrén Eriksson Communications Director

2017

2017 (4) 25,000 B-shares

Hans Basun Chief Medical Officer

2007

2007 20,823 B-shares

1,818 (3)

Johanna Fälting Head of the Department for Immunology and Pharmacology

2012

2012 10,000 B-shares

1,818 (3)

Pär Gellerfors Senior Vice President Business Strategy (5)

2003

2003 5,759,998 A-shares
18,026,393 B-shares

Mats Holmquist Responsible for Quality Assurance

2008

2008

1,818 (3)

Mikael Moge Head of the Department for Biochemistry and Molecular Biology

2012

2012

455 (6)

Christer Möller Chief Scientific Officer

2006

2006 16,500 B-shares

1,818 (3)

(1) Refers to shares (“SH”) and call options (“CO”) held in their own name as well as by affiliated natural and legal persons.
(2) The options entitle to subscription of 87,270 B-shares in the Company. Deputy CEO 2013 and CEO of the Company since 2014.
(3) The options entitle to subscription of 27,270 B-shares in the Company.
(4) The assignment is carried out on a consultancy basis.
(5) Pär Gellerfors is co-opted member of the management team. During 2003-2014 he was the CEO of the Company.
(6) The options entitle to subscription of 6,825 B-shares in the Company.